ArticleCurrent issues in molecular biology2025
A PDCD4-Based Gene Expression Signature Predicts Overall Survival in Renal Cell Carcinoma: A TCGA-Based Discovery and External Validation Study.
Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is a heterogeneous disease with variable clinical outcomes. PDCD4 functions as a tumor suppressor, but its role in RCC prognosis remains unclear. We aimed to develop and validate a PDCD4-based gene expression signature for predicting overall survival in RCC. We analyzed RNA-seq data from 541 clear cell RCC patients in The Cancer Genome Atlas (TCGA-KIRC). We identified 100 genes (50 positively and 50 negatively correlated with PDCD4) to create a prognostic signature. Patients were stratified into high- and low-signature groups using median cutoff. Kaplan-Meier analysis and Cox regression models assessed prognostic value. External validation was performed in four independent cohorts: GSE29609, GSE73731, GSE53757, and GSE40435. Low PDCD4 signature scores were associated with significantly worse overall survival (HR = 2.17, 95% CI: 1.58-2.98,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.